

## **REMARKS**

By the present amendment, applicants have cancelled Claims 30, 32, 38-40, and 44-50 since the claims are drawn to a non-elected invention. Therefore, the claims remaining for consideration by the Examiner are Claims 29, 31, 33-37, and 41-43.

The Examiner has required restriction under 35 U.S.C. § 121 and 372 to the subject matter of:

Group I: Claims 29, 31, 33-37, and 41-42, drawn to products of a potassium salt of losartan in crystal form X.

Group II: Claims 30 and 38, drawn to products of a potassium salt of losartan in crystal form Y.

Group III: Claim 39, drawn to a method for treating hypertension in a patient comprising administering the potassium salt of losartan in crystal form X.

Group IV: Claim 40, drawn to a method for treating hypertension in a patient comprising administering the potassium salt of losartan in crystal form Y.

Group V: Claim 44, drawn to a crystalline sodium salt of losartan characterized by a powder X-ray diffraction pattern as depicted in Figure 21.

Group VI: Claim 45, drawn to a crystalline sodium salt of losartan.

Group VII: Claim 46, drawn to a crystalline sodium salt of losartan having the IR spectrum as depicted in Figures 11 and 12.

Group VIII: Claim 47, drawn to a crystalline sodium salt of losartan characterized by a powder X-ray diffraction pattern as depicted in Figure 24.

Group IX: Claim 48, drawn to a crystalline sodium salt of losartan having the IR spectrum as depicted in Figure 16.

Group X: Claim 49, drawn to a crystalline sodium salt of losartan having a DSC thermogram as depicted in Figure 8.

Group XI: Claim 50, drawn to a crystalline sodium salt of losartan having a DSC thermogram as depicted in Figure 3.


In response to the Restriction Requirement, applicants elect to prosecute the invention of Group I, Claims 29, 31, 33-37 and 41-43, without traverse. Claim 43 was not attributed to a group designated by the Examiner. As Claim 43 is clearly directed to losartan in crystal form X,

applicants respectfully request that Claim 43 be included in Group I. Therefore, applicants have included Claim 43 in Group I.

Reconsideration and allowance of the pending claims is requested.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(609) 627-8507

  
\_\_\_\_\_  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

Date: *August 15, 2006*